Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 4—April 2016

Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali

Nafomon Sogoba, Kyle Rosenke, Jennifer Adjemian, Sory Ibrahim Diawara, Ousmane Maiga, Moussa Keita, Drissa Konaté, Abdoul Salam Keita, Ibrahim Sissoko, Matt Boisen, Diana Nelson, Darin Oottamasathien, Molly Millett, Robert F. Garry, Luis M. Branco, Sékou F. Traoré, Seydou Doumbia, Heinz Feldmann, and David SafronetzComments to Author 
Author affiliations: University of Sciences, Techniques and Technologies of Bamako, Bamako, Mali (N. Sogoba, S.I. Diawara, O. Maiga, M. Keita, D. Konaté, A.S. Keita, I. Sissoko, S.F. Traoré, S. Doumbia); National Institutes of Health, Hamilton, Montana, USA (K. Rosenke, H. Feldmann, D. Safronetz); National Institutes of Health, Bethesda, Maryland, USA (J. Adjemian); Corgenix Medical Corporation, Inc., Broomfield, Colorado, USA (M. Boisen, D. Nelson, D. Oottamasathien, M. Millett); Tulane School of Medicine, New Orleans, Louisiana, USA (R.F. Garry); Zalgen Labs LLC, Germantown, Maryland, USA (L.M. Branco); Public Health Agency of Canada, Winnipeg, Manitoba, Canada (D. Safronetz)

Main Article

Table 1

Lassa virus IgG seroprevalence by study site, southern Mali, 2015

Village Male participants, no.
positive/no. total (%) Female participants, no.
positive/no. total (%) Combined seroprevalence, no. positive/no. total Combined seroprevalence, % (95% CI)
Bamba 35/95 (37.2) 53/105 (50.5) 88/200 44.0 (37.0–51.2)
Banzana 14/95 (14.7) 15/105 (14.3) 29/200 14.5 (9.9–20.2)
Soromba 39/95 (41.1) 43/105 (41.0) 82/200 41 (34.1–48.2)
Total 88/285 (30.9) 111/315 (35.2) 199/600 33.2 (29.4–37.1)

Main Article

Page created: March 15, 2016
Page updated: March 15, 2016
Page reviewed: March 15, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.